Clinical Trials Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Total 567 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients

Epilepsy | Epilepsy, Generalized | Seizures | Epilepsies, Partial
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study on Efficacy and Safety of Topiramate in the Treatment of Patients With Obesity

Obesity
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program

Obesity
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.

Schizophrenia | Schizoaffective Disorders
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder | Attention Deficit Disorders With Hyperactivity
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia

Schizophrenia

United States
Basilea Pharmaceutica
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients

Obesity | Streptococcal Infections | Staphylococcal Skin Infections
Basilea Pharmaceutica
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age

Streptococcal Infections | Staphylococcal Skin Infections
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

Urologic Diseases | Urinary Bladder Diseases | Cystitis | Cystitis, Interstitial

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis

Pain | Osteoarthritis | Joint Pain | Arthralgia | Osteoarthritis, Knee

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

Pain | Osteoarthritis | Joint Pain | Arthralgia | Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, Canada, Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Withdrawn

A Study to Evaluate Folate Levels in Women Taking Oral Contraceptives

Nervous System Malformations | Neural Tube Defects | Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Healthy

India
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Diabetic Neuropathy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adults

Allergic Rhinitis

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Nutritional and Metabolic Diseases

United Kingdom, Germany, Belgium, Poland, India, Finland, Sweden, Netherlands, Russian Federation, Norway, Denmark
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia

Schizophrenia

United States, Taiwan, India
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Safety and Pharmacokinetic Study of Paliperidone Palmitate in Patients With Schizophrenia

Schizophrenia

Poland, United States, Belgium, Taiwan, Spain, Malaysia, Korea, Republic of, Thailand, Slovakia, Croatia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Rheumatoid Arthritis

United States, Poland, Germany, Mexico, Brazil, Czech Republic, Argentina
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

Malabsorption Syndromes | Cystic Fibrosis | Steatorrhea | Exocrine Pancreatic Insufficiency

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

Autistic Disorder | Autism

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

Schizophrenia

United States, Colombia, Ukraine, Argentina, Czech Republic, Slovakia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

Anemia

United States, Puerto Rico
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of Single and Multiple Ascending Doses of JNJ-41443532 in Healthy Male Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic and Bioavailability Study of 28431754 (Canagliflozin) in Healthy Male Volunteers

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

Atopic Dermatitis

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers

Healthy Volunteer
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy Study of JNJ-39220675 and Pseudoephedrine in Participants With Allergic Rhinitis

Allergic Rhinitis

Canada
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid Dosage Formulation(s) of JNJ-40411813

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study To Investigate The Effect of JNJ-39758979 on Histamine Induced Itch in Healthy Male Volunteers

Histamine Induced Itch

United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin

Diabetes Mellitus, Type 2

United States
Johnson & Johnson Pharmaceutical Research & Development...

Withdrawn

A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies

Anemia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers

Healthy Volunteers
Johnson & Johnson Pharmaceutical Research & Development...

Completed

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Diabetes Mellitus, Type II | Diabetes Mellitus, Non Insulin Dependent

United States, Poland, Bulgaria, India, Malaysia, Romania, Canada, Russian Federation, Argentina, Puerto Rico, Czech Republic, United Kingdom, Mexico
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes

Obesity

United States, Puerto Rico
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants

Rheumatoid Arthritis

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain Injury

Traumatic Brain Injury

France, Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa

Pure Red-cell Aplasia

United Kingdom, Sweden, South Africa, Brazil, Norway, France, Thailand
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment

Pure Red-cell Aplasia

United Kingdom, Sweden, South Africa, Brazil, Canada, Germany, Norway, Thailand
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Two Methods for Determining the Renal Threshold for Glucose in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Germany

Clinical Trials Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations